Safety & Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, &

Status Recruiting

Clinical Trial Summary

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and dexamethasone 40 mg orally on Days 1 through 4. Epcoritamab will be administered subcutaneously (SC) on Days 1, 8, and 15. Patients will receive granulocyte colony stimulating factor (G-CSF) between Day 8 through Day 10 of each cycle of combination therapy. Patients will then undergo radiology imaging for disease assessment. Patients may proceed to SCT(autologous or allogeneic) or CAR T-cell therapy or epcoritamab monotherapy upon completion of Cycle 3 per investigator discretion. The rationale for subjects not proceeding to autoSCT or CAR T-cell therapy will be captured in the eCRFs. Patients who do not undergo SCT or CAR T-cell therapy may have the option to receive study treatment with epcoritamab monotherapy following completion of Cycle 3. Epcoritamab monotherapy will be offered to selected subjects who become ineligible to undergo SCT or CAR T-cell therapy (such as social situation, change in subject decision). The decision to offer epcoritamab monotherapy will be per investigator's discretion. However, subjects must have demonstrated a response to the combination therapy (partial remission or complete remission) per disease assessment scans prior to offering epcoritamab monotherapy. Epcoritamab monotherapy should begin 2 weeks following Cycle 3 Day 15. Monotherapy will consist of epcoritamab 48 mg administered subcutaneously on Days 1 and 15 of each 28 day cycle for Cycle 4 to Cycle 9 or until unacceptable toxicity, or disease progression per the Lugano Criteria.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05852717
Study type	Interventional
Source	Hoosier Cancer Research Network
Contact	Dipenkumar Modi, MD
Phone	313-576-8739
Email	modid@karmanos.org
Status	Recruiting
Phase	Phase 2
Start date	October 31, 2023
Completion date	June 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03336931` - PRecISion Medicine for Children With Cancer
Completed	`NCT00530192` - Molecular Profiling Protocol (SCRI-CA-001)	Phase 0
Recruiting	`NCT06229340` - Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations	Phase 2
Completed	`NCT00551850` - A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients	Phase 1
Recruiting	`NCT06104488` - A Study of Avutometinib for People With Solid Tumor Cancers	Phase 1
Terminated	`NCT04092179` - Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers	Phase 1/Phase 2
Recruiting	`NCT06184035` - A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer	Phase 1/Phase 2
Recruiting	`NCT06024603` - Individualized Treatments in Adults With Relapsed/Refractory Cancers	N/A
Recruiting	`NCT05859074` - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Phase 1
Recruiting	`NCT05864144` - A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03187288` - Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS	Phase 1
Terminated	`NCT01320280` - BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer	Phase 2
Completed	`NCT03441100` - TCR-engineered T Cells in Solid Tumors: IMA202-101	Phase 1
Recruiting	`NCT05359445` - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors	Phase 1
Recruiting	`NCT03686124` - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors	Phase 1
Recruiting	`NCT04337580` - Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer	Phase 2
Active, not recruiting	`NCT04310345` - Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents	N/A
Recruiting	`NCT05669430` - A Study of GV20-0251 in Patients With Solid Tumor Malignancies	Phase 1
Not yet recruiting	`NCT06208657` - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	Phase 1/Phase 2
Recruiting	`NCT05662397` - A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms